VRXA Veraxa Biotech AG
Mergers ·
Veraxa Biotech says its business combination with Voyager Acquisition Corp. has closed, and its shares and warrants were due to start trading on the Nasdaq Capital Market on June 11, 2026. The company cites a $27.5 million senior secured note and a share purchase agreement for up to $50 million.
The Form F-4 for Veraxa Biotech Holding AG is dated July 16, 2025 and covers the business combination with Voyager Acquisition Corp. under an agreement dated April 22, 2025. The date of Voyager's shareholder meeting is still blank.
Veraxa Biotech AG describes itself as an oncology-focused biotechnology and clinical drug development company. Its research and development is carried out by its wholly owned subsidiary, VERAXA Biotech GmbH, based in Heidelberg, Germany. The company's technologies include antibody modulation technology from Araxa Bioscience GmbH, droplet-based microfluidic screening technology from Velabs Therapeutics GmbH, and a Hemibody platform in-licensed from Cherry Biolabs GmbH. The Hemibody platform is described as the precursor of its proprietary BiTAC-TCE platform. Through its acquisition of Synimmune GmbH, the company acquired VX-A901 (formerly FLYSIN), an antibody that the text says completed a Phase I trial for acute myeloid leukemia. Synimmune was described as active in anti-tumor antibodies for rare hematopoietic malignancies. The company's patent disclosures cover microfluidic droplet detection and sorting, relevant to its Hitmaster antibody screening technology. The filing says the business combination with PubCo was consummated on June 10, 2026, with PubCo as the surviving company after the merger.
| Product or program | What it is | Stage |
|---|---|---|
| VX-A901 (formerly FLYSIN) | Anti-tumor antibody for acute myeloid leukemia | completed a Phase I trial |
| BiTAC-TCE platform | Proprietary platform for oncology drug development, derived from the Hemibody platform | |
| Hemibody platform | Platform in-licensed from Cherry Biolabs, precursor of BiTAC-TCE | |
| Hitmaster microfluidic antibody screening | Microfluidics-based antibody screening technology |
Our latest story on this, dated Jun 11, 2026: "Veraxa Biotech closes Voyager SPAC merger, Nasdaq trading starts June 11". The story links the filing or release it is based on. Read the story.
Veraxa Biotech AG trades under the ticker VRXA on NASDAQ.
Veraxa Biotech AG is listed on NASDAQ.
The SEC Central Index Key (CIK) for Veraxa Biotech AG is 2079109. Its filings are on SEC EDGAR.
Our directory records Veraxa Biotech AG under Switzerland.
Our directory classifies Veraxa Biotech AG as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Veraxa Biotech AG is CH1476899161.
aibio.space lists Veraxa Biotech AG among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as V8.
Veraxa Biotech AG describes itself as an oncology-focused biotechnology and clinical drug development company. Its research and development is carried out by its wholly owned subsidiary, VERAXA Biotech GmbH, based in Heidelberg, Germany.
VX-A901 (formerly FLYSIN): Anti-tumor antibody for acute myeloid leukemia Stage: completed a Phase I trial.
BiTAC-TCE platform: Proprietary platform for oncology drug development, derived from the Hemibody platform
Our latest story on Veraxa Biotech, dated Jun 11, 2026: "Veraxa Biotech closes Voyager SPAC merger, Nasdaq trading starts June 11". Veraxa Biotech says its business combination with Voyager Acquisition Corp. has closed, and its shares and warrants were due to start trading on the Nasdaq Capital Market on June 11, 2026. The company cites a $27.5 million senior secured note and a share purchase agreement for up to $50 million. Source.
From our story of Jul 31, 2025: Veraxa's independent auditor's report for 2024 includes an explanatory paragraph expressing substantial doubt about its ability to continue as a going concern, and the filing says the company will need substantial additional capital even after the combination closes. Source.
SEC records list Veraxa Biotech AG's filer category as: <br>Emerging growth company.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio